The global Generalized Myasthenia gravis (GMG) market size is expected to surpass an impressive valuation of USD 1.32 Billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 7.6% from 2023 to 2033.
Generalized Myasthenia gravis (GMG) is an infrequent autoimmune disease that leads to skeletal muscle tiredness and weakness owing to antibodies that consequence interrupted interaction between muscles and nerves. With a geriatric population, the worldwide incidence of the disorder has risen over the past decade.
According to a National Library of Medicine report, the incidence of generalized myasthenia gravis (GMG) in the USA is 20 per 100,000 people. It has a female pervasiveness in those under 40 years old and a male primacy in those over 50 years old. Childhood MG is rare in Western populations but familiar in Asian nations, affecting approximately 50% of patients under the age of 15. According to reports, the disorder's prevalence appears to have risen in recent decades. This could be due to improved healthcare data, but diseases, in general, are becoming more common around the world.
Several organizations, authorities, and sectors are working to raise public and individual awareness of the disorder. For example, the Myasthenia Gravis Foundation of America (MGFA) is publicizing various ways to recognize June as Myasthenia Gravis Awareness Month. The foundation runs a publicity campaign in which they provide a 23-page toolkit and educate people about the ailment and available treatments. As an outcome, the patient population seeking treatment for the ailment expands.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1.32 Billion |
| Anticipated Forecast Value (2033) | USD 2.96 Billion |
| Projected Growth Rate (2023 to 2033) | 7.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
COVID-19 has had an unexpected and astounding global impact, with generalized myasthenia gravis (GMG) treatment suffering a detrimental effect throughout all regions during the disease outbreak. According to our assessment, the global market grew at a slower pace of 4.6% in 2020 than the average annual growth from 2017 to 2019. The sharp rise in CAGR is due to this industry's revenue and growth rate, which recovered to pre-pandemic stages once the pandemic was over.
The diagnosis proportion among people is rising as the disease's incidence and consciousness grow. As a consequence, the number of individuals requiring treatment is expanding. For instance, the global incidence of generalized myasthenia gravis (GMG) disorder is approximated to be 12.5 people per 100,000 people. Myasthenia gravis patients are on the rise, having more than doubled in the past 20 years. Prolonged innovation and research into new therapies with the patient populace's present unmet medical needs, is expected to lead to higher consumption of novel therapeutics over the projected timeframe.
The increased incidences of Myasthenia Gravis drive market growth
Globally, the disease's incidence has risen substantially in recent years. This rise could be attributed to increased disease awareness and diagnosis rates in both developed and developing nations. The nations' vastly improved reimbursement guidelines for the disorder are also cruising sales growth. Furthermore, based on a study conducted by the National Organization for Rare Disorders (NORD), the condition's prevalence in the United Kingdom is estimated to be 15 per 100,000 people, a figure that has risen over time. The popularity of novel therapeutic approaches is growing in tandem with the escalating diagnosis speed and favorable reimbursement guidelines for the ailment.
This is raising the attempts of the industry's prominent stakeholders to establish and obtain approval for novel drugs to treat the illness. For example, F. Hoffmann-La Roche Ltd has a drug in production for the treatment of generalized myasthenia gravis (GMG) called Enspyrng, with a filing date of 2024. During the forecast timeframe, these aspects are predicted to propel the market.
The growing geriatric population drives market expansion
The age structure of the population is another factor driving the market growth. As per Eurostat, more than one-fifth (20.8%) of the European population was estimated to be 65 or older in 2021. The proportion of people aged 80 and up in the EU population is predicted to more than double between 2021 and 2100, soaring from 6.0% to 14.6%. Based on the MDPI Journal of Clinical Medicine, the prevalence of the ailment rises progressively with age. The 60-89-year-old age group has the greatest incidence. As a result, the disease's prevalence is increasing as the population's average lifespan rises.
Based on a 2020 epidemiology of myasthenia gravis article posted by Value in Health Journal, the older population has a higher incidence of the ailment than younger ages. In the United Kingdom, for example, the pervasiveness of the disorder in the aging population was 46.4 per 100,000, in comparison to 12 per 100,000 in young adulthood.
Principal Consultant
High treatment costs and insufficient reimbursement policies in emerging markets to stymie market growth
The elevated treatment costs and insufficient reimbursement policies in developing countries are predicted to stifle market sales growth. Based on the results of a recent survey of generalized myasthenia gravis (GMG) (MG) patients and their families, the financial burden of surviving the illness is substantial, as indicated by out-of-pocket payouts that are estimated more than USD 14,000 annually.
Rising incidence of the disease and the region's aging population drive market growth
In 2020, the North American market was worth USD 0.58 billion. The soaring incidence of the illness and the region's aging population are the contributing factors to market growth during the forecast period. Furthermore, the region's established healthcare facilities and favorable reimbursement policies are striving to improve diagnosis and therapy rates in both emerging and advanced economies. For instance, on September 6, 2022, the Myasthenia Gravis Foundation of America and the PAN Foundation revealed a new partnership to assist patients staying with generalized myasthenia gravis (GMG), providing up to USD 13,000 annually in financial help and other facilities to patients and their family members.
Another factor causing market revenue growth is the growing number of clinical trials and approvals. For example, on April 28, 2022, the USA Food and Drug Administration (FDA) authorized Ultomiris, a lengthy C5 complement inhibitor established by AstraZeneca, for the treatment of patients with generalized myasthenia gravis. As a result, the aforementioned factors are predicted to boost industry growth in the region throughout the forecast period.
Favorable reimbursement policies for treatment to drive the regional market
The Asia Pacific market revenues are anticipated to expand at a rapid rate during the forthcoming years, owing to the rising prevalence of generalized myasthenia gravis (GMG) and the availability of more favorable reimbursement policies for treatment, which is increasing the recurrence of diagnosis in addition to the number of people receiving treatment. For instance, Ultomiris (ravulizumab) was approved in Japan in August 2022 for the treatment of adult individuals with generalized myasthenia gravis (gMG) who have anti-acetylcholine receptor (AChR) antibodies and whose ailments are difficult to treat with elevated IVIg or plasmapheresis
Also, based on a 2020 study published in the Journal of the Formosan Medical Association in Australia, generalized myasthenia gravis (GMG) accounted for approximately 8.1% of the top ten indications for IVIg. These aspects are expected to propel the market's expansion in the region over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By End-User, Which Segment is Projected to Lead the Market? The growing number of hospital admissions has aided hospitals to dominate the industry in 2021 In 2021, the hospital segment held the lion's share. This is caused by a rise in hospitalizations and doctor visits. As a result of the side effects of the drugs, approximately 15-20% of patients develop a myasthenia crisis throughout their duration of treatment, necessitating hospitalization. Furthermore, the well-established medical infrastructure in industrialized economies is a factor driving this segment's expansion. Which Drug Type Segment Will Generate High Revenue? Monoclonal antibodies segment to grow rapidly owing to its potential efficacy The monoclonal antibodies segment is expected to grow at a rapid rate throughout the forecast period, attributable to the disease's worldwide increased incidence and rising demand for particular therapeutics for its treatment. Tocilizumab, inebilizumab, rozanolixizumab, nipocalimab, satralizumab, and pozelimab are just a few of the monoclonal antibodies being studied for their potential efficacy as a treatment for generalized myasthenia gravis (GMG).
Key players in the Generalized Myasthenia Gravis (GMG) Management market are Alexion Pharmaceuticals, Argenx, UCB Biopharma, Horizon Therapeutics, Halozyme Therapeutics, Hoffmann-La Roche AG, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1.32 Billion |
| Anticipated Forecast Value (2033) | USD 2.96 Billion |
| Projected Growth Rate (2023 to 2033) | 7.6% CAGR |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Type, Material, End-user, Application, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa (MEA) |
| Key Countries Profiled | United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Alexion Pharmaceuticals; Argenx; UCB Biopharma; Horizon Therapeutics; Halozyme Therapeutics; Hoffmann-La Roche AG; Janssen Research & Development; LLC, Immunovant Sciences GmbH; Sanofi; Cartesian Therapeutics |
| Customization | Available Upon Request |
The market is valued at USD 1.32 billion in 2023.
The market is estimated to reach USD 2.96 billion by 2033.
The increased incidences of Myasthenia Gravis and the growing geriatric population drive market expansion.
High treatment costs and insufficient reimbursement policies in emerging markets limit growth potential.
The hospital segment is projected to lead the market.
1. Executive Summary | Generalized Myasthenia Gravis (GMG) Management Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Treatment 5.1. Drug Types 5.1.1. Monoclonal Antibodies 5.1.2. FcRn Inhibitors 5.1.3. Corticosteroids 5.1.4. Cholinesterase Inhibitors 5.2. Pharmacotherapy 5.3. Therapeutic Plasma Exchange 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By End Users 6.1. Hospitals 6.2. Specialty Clinics 6.3. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033 By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Alexion Pharmaceuticals 15.2. Argenx 15.3. UCB Biopharma 15.4. Horizon Therapeutics 15.5. Halozyme Therapeutics 15.6. F. Hoffmann-La Roche AG 15.7. Janssen Research & Development, LLC 15.8. Immunovant Sciences GmbH 15.9. Sanofi 15.10. Cartesian Therapeutics 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Generalized Myasthenia Gravis (GMG) Managements Market
